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Abstract
Background:  The human fibroblast growth factor (FGF) and its receptor (FGFR) play an
important role in tumorigenesis. Deregulation of the FGFR2 gene has been identified in a number
of cancer sites. Overexpression of the FGFR4 protein has been linked to cutaneous melanoma
progression. Previous studies reported associations between genetic variants in the FGFR2 and
FGFR4 genes and development of various cancers.
Methods: We evaluated the associations of four genetic variants in the FGFR2 gene highly related
to breast cancer risk and the three common tag-SNPs in the FGFR4 gene with skin cancer risk in a
nested case-control study of Caucasians within the Nurses' Health Study (NHS) among 218
melanoma cases, 285 squamous cell carcinoma (SCC) cases, 300 basal cell carcinoma (BCC) cases,
and 870 controls.
Results: We found no evidence for associations between these seven genetic variants and the risks
of melanoma and nonmelanocytic skin cancer.
Conclusion: Given the power of this study, we did not detect any contribution of genetic variants
in the FGFR2 or FGFR4 genes to inherited predisposition to skin cancer among Caucasian women.
Background
The human fibroblast growth factor (FGF) and its receptor
families consist of 22 structurally related FGF members
and four high-affinity tyrosine kinase FGF receptors
(FGFR1 to 4) [1,2]. The four FGFRs generate ligand-bind-
ing specific isoforms by tissue-specific alternative mRNA
splicing of the genes [3-7]. FGFs and their receptors have
an important role in cell signaling [8]. The formation of
the FGF-FGFR complex activates the intracellular tyrosine
kinase, which mediates signal transduction through the
direct phosphorylation of adaptor proteins [9]. These
complex FGF signaling networks are crucial in the multi-
ple cell biological activities, such as proliferation, differ-
entiation, mitogenesis, migration, and apoptosis, and are
thus implicated in tumorigenesis [10-12].
The FGFR2, known as a unique high-affinity receptor for
keratinocyte growth factor (KGF or FGF7), is expressed in
the keratinocytes of the skin epidermis, hair follicles, and
mesenchymal tissues [5,13,14]. An experiment in trans-
genic mice with FGFR2  mutation in the keratinocyte
showed that normal signal transduction was blocked by
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binding of its ligand KGF [15]. It has been reported that
the FGFR2 plays a role in tumor suppression in the skin
[16]. In addition, the increased FGFR2 gene expression
has been related to the genetic variants in intron 2 of the
FGFR2 gene [17] and deregulation of FGFR2 gene expres-
sion and/or gene mutation has been identified in various
kinds of human cancers, such as breast, prostate, endome-
trial, colon, bladder, and thyroid cancers [17-22].
Recently, two genome-wide association studies have iden-
tified some genetic variants in the FGFR2 gene that were
highly associated with breast cancer [23,24].
The  FGFR4  gene located on the chromosome 5 spans
approximately 11.3 kb and is composed of 18 exons [25].
Overexpression of the FGFR4 protein has been associated
with cutaneous melanoma progression [26]. High expres-
sion of FGFR4 has also been observed in breast cancer,
prostate cancer, pancreatic cancer, and renal cell carci-
noma [27-30]. Furthermore, SNP rs351855 located in
exon 9 of the FGFR4 gene results in an amino acid change
(Gly388Arg) in the transmembrane domain of the recep-
tor and has been associated with tumor progression in, for
example, cutaneous nodular malignant melanoma, breast
cancer, lung adenocarcinoma, prostate cancer, and head
and neck cancer [26,31-36].
We conducted a nested case-control study of Caucasians
within the Nurses' Health Study (NHS) to evaluate
whether the four breast cancer-related SNPs in the FGFR2
gene (rs11200014, rs2981579, rs1219648, and
rs2420946) [24] and the three common variants (tag-
SNPs) in the FGFR4  gene (rs1966265, rs376618, and
rs351855) are associated with the risk of three skin cancer
types including melanoma, squamous cell carcinoma
(SCC), and basal cell carcinoma (BCC).
Methods
Eligible cases in this study consisted of women with inci-
dent skin cancer from the subcohort of the NHS who gave
a blood specimen in 1989–1990 (n = 32,826), including
SCC and BCC cases with a diagnosis any time after blood
collection up to June 1, 1998 and melanoma cases up to
June 1, 2000 with no previously diagnosed skin cancer. A
common control series was randomly selected from par-
ticipants who gave a blood sample and were free of diag-
nosed skin cancer up to and including the questionnaire
cycle during which the case was diagnosed. One or two
controls were matched to each case by year of birth (± 1
year). All subjects were drawn from the U.S. non-Hispanic
Caucasian women in this study. The nested case-control
study consisted of 218 incident melanoma cases, 285 inci-
dent SCC cases, a sample of 300 BCC cases from the large
number of incident cases, and 870 age-matched controls.
The informed consent was obtained from the participants
in this study. The study protocol was approved by the
Committee on Use of Human Subjects of the Brigham and
Women's Hospital, Boston, MA.
We obtained information regarding skin cancer risk fac-
tors from the prospective biennial questionnaires and a
retrospective supplementary questionnaire. Information
on natural hair color at age 20 and childhood and adoles-
cent tanning tendency were collected in the 1982 prospec-
tive questionnaire. Ethnic group was ascertained in the
1992 questionnaire. In the skin cancer nested case-control
study, natural skin color and other sun exposure-related
information were collected by the retrospective supple-
mentary questionnaire in 2002. The response rates of
cases and controls were 92% and 89%, respectively. A
cumulative lifetime sun exposure while wearing a bathing
suit for each individual was developed by combining the
UV database and the information obtained from the sup-
plementary questionnaires. We constructed a multivariate
confounder score to create a constitutional susceptibility
score [37], summarizing natural skin color, natural hair
color, child or adolescent tendency to burn, and the
number of palpably raised moles on arms. We used this
score to define women with constitutional susceptibility
[38]. In addition, the 11 states of residence of cohort
members at baseline were grouped into three regions:
Northeast (Connecticut, Massachusetts, Maryland, New
Jersey, New York, and Pennsylvania), Northcentral (Mich-
igan and Ohio), and West and South (California, Texas,
and Florida).
Information on the seven SNPs in the FGFR2 and FGFR4
genes is presented in Table 1. Four SNPs in intron 2 of the
FGFR2  gene (rs11200014, rs2981579, rs1219648, and
rs2420946) genotyped in this study were breast cancer-
related SNPs identified by a recent genome-wide associa-
tion study conducted by our group [24]. For the FGFR4
gene, based on the HapMap phase II SNP genotype data,
we chose three tag-SNPs (rs1966265, rs376618, and
rs351855) as surrogates for untyped polymorphisms in
the FGFR4 gene using the HapMap Project 90 (30 trios)
Caucasian samples from a US Utah population with
Northern and Western European ancestry collected in
1980 by the Centre d'Etude du Polymorphisme Humain
(CEPH) [39]. Briefly, the tag-SNPs (minor allele fre-
quency > 0.05) were selected using the Tagger program of
(r2>0.8), which combines the simplicity of pairwise r2
methods [40] with the potential efficiency of multimarker
haplotype approaches [41].
We genotyped these seven SNPs by the 5' nuclease assay
(TaqMan®) in 384-well format, using the ABI PRISM 7900
HT Sequence Detection System (Applied Biosystems, Fos-
ter City, CA). TaqMan® primers and probes were designed
with the Primer Express® Oligo Design software v2.0 (ABI
PRISM). Due to assay failure, we genotyped rs12519145BMC Cancer 2009, 9:172 http://www.biomedcentral.com/1471-2407/9/172
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as a surrogate for the FGFR4 rs1966265 (r2 = 0.8). Labora-
tory personnel were blinded to case-control status, and
10% blinded quality control samples (duplicate samples)
were inserted to validate genotyping procedures; concord-
ance for the blinded quality control samples was 100%.
Primers, probes, and conditions for genotyping assays are
available upon request.
We used the χ2 test to assess whether the genotypes for all
seven SNPs were in Hardy-Weinberg equilibrium among
the controls. We compared each type of skin cancer with
the common control series to increase the statistical
power. We evaluated the association between each geno-
type and skin cancer risk using unconditional logistic
regression. An additive model was used to calculate the p-
value on skin cancer risk according to an ordinal coding
for genotype (0, 1 or 2 copies of SNP minor allele). For the
four FGFR2 SNPs and three FGFR4 SNPs, haplotype fre-
quencies and expected haplotype counts for each individ-
ual were estimated using a simple expectation-
maximization algorithm, as implemented in SAS PROC
HAPLOTYPE. The analyses of the associations between
haplotypes and skin cancer risk were performed using the
expectation-substitution technique [42]. All statistical
analyses were two-sided and carried out using SAS V9.1
(SAS Institute, Cary, NC).
The Quanto statistical software version 1.2.3 was used for
power calculation [43]. We calculated the power to detect
the specified ORs at various allele frequencies of variant
allele in additive models. The calculations were based on
a two-sided alpha of 0.05. For melanoma (SCC or BCC),
we have 80% power to detect an OR of 1.80 (1.72 or
1.70), 1.48 (1.42 or 1.41), and 1.35 (1.32 or 1.31) if the
minor allele frequency is 5%, 15%, and 40%, respectively.
Results and discussion
A detailed description of the characteristics of cases and
controls in the skin cancer nested case-control study has
been provided previously [44]. In brief, at the beginning
of the follow-up of this nested case-control study, the
nurses were between 43 and 68 years old (mean age, 58.7
years). The mean ages at diagnosis for incident
melanoma, SCC, and BCC cases were 63.4, 64.7, and 64.0
years, respectively. A family history of skin cancer was a
risk factor for all three types of skin cancer. Skin cancer
cases had lighter pigmentation (skin color and hair color),
more moles on the arms, higher cumulative sun exposure
while wearing a bathing suit, and more lifetime severe
sunburns that blistered than controls.
The genotype distributions of the seven SNPs evaluated in
this study were in Hardy-Weinberg equilibrium among
controls. The minor allele frequencies of these seven SNPs
among controls in this study were similar to those from
HapMap CEU data. We evaluated the main effect of each
polymorphism across three types of skin cancer (Table 2)
and observed no significant associations between these
seven SNPs and skin cancer risk. The multivariate analyses
controlling for age and skin cancer risk factors showed
results similar to the age-adjusted analyses (Additional
file 1). Furthermore, we performed a global test to evalu-
ate the difference in FGFR2  and  FGFR4  haplotype fre-
quencies between cases and controls (Table 3) and found
no significant associations with skin cancer risk, which
was consistent with the results of the single SNP analyses
presented in Table 2.
The potential contribution of the FGF/FGFR family to the
development of skin cancer has been suggested. For exam-
ple, the basic FGF (bFGF) alternatively named FGF2 binds
to distinct splice variants of the four FGFRs and acts as a
potent activator in the proliferation and differentiation of
melanocytes [45]. It has been noted that the combination
of bFGF with ultraviolet (UV) light, the main risk factor
for skin cancer, may lead to cutaneous melanoma induc-
tion [46]. In this study, we assessed the associations
between the genetic variants in the FGFR2  and FGFR4
genes and the three types of skin cancer simultaneously
with a modest sample size in each cancer type. Only one
Table 1: Seven SNPs in the FGFR2 and FGFR4 genes
SNP rs# Chromosome Location MAF-controls (%)a MAF-CEU (%)b
FGFR2 intron 2 rs11200014 10 123324920 42 47
FGFR2 intron 2 rs2981579 10 123327325 42 47
FGFR2 intron 2 rs1219648 10 123336180 40 47
FGFR2 intron 2 rs2420946 10 123341314 40 47
FGFR4 Val10Ile rs1966265* 5 176449237 - 20
rs12519145* 5 176488129 22 19
FGFR4 Leu136Pro rs376618 5 176450403 24 26
FGFR4 Gly388Arg rs351855 5 176452849 31 28
*The SNP rs1966265 failed the assay and the rs12519145 was genotyped instead (r2 = 0.8).
a Minor allele frequency (MAF) was calculated among controls in this study.
b MAF was based on the HapMap CEU (Utah residents with ancestry from northern and western Europe) samples.BMC Cancer 2009, 9:172 http://www.biomedcentral.com/1471-2407/9/172
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Table 2: Associations between the seven SNPs in the FGFR2 and FGFR4 genes and skin cancer risk
SNP Melanoma SCC BCC
Additive OR* p for trend Additive OR* p for trend Additive OR* p for trend
FGFR2 rs11200014 0.95 (0.77–1.19) 0.67 0.90 (0.74–1.10) 0.30 1.03 (0.85–1.26) 0.73
FGFR2 rs2981579 0.96 (0.77–1.19) 0.70 0.92 (0.75–1.12) 0.40 1.11 (0.91–1.36) 0.29
FGFR2 rs1219648 0.96 (0.77–1.20) 0.75 0.87 (0.71–1.07) 0.18 1.06 (0.87–1.29) 0.57
FGFR2 rs2420946 1.08 (0.85–1.38) 0.53 0.89 (0.72–1.10) 0.28 0.99 (0.81–1.21) 0.91
FGFR4 rs1966265** 1.16 (0.90–1.48) 0.26 1.00 (0.79–1.26) 1.00 0.94 (0.74–1.19) 0.61
FGFR4 rs376618 0.88 (0.67–1.14) 0.33 1.04 (0.83–1.31) 0.73 0.87 (0.69–1.11) 0.27
FGFR4 rs351855 1.09 (0.87–1.38) 0.44 0.90 (0.73–1.12) 0.35 1.13 (0.93–1.39) 0.21
*Unconditional logistic regression adjusted for age.
**The SNP rs1966265 failed the assay and the rs12519145 was genotyped instead (r2 = 0.8).
Table 3: Haplotypes for the SNPs in the FGFR2 and FGFR4 genes and skin cancer risk
FGFR2 Melanoma SCC BCC
Controls Cases Cases Cases
A B C D n%n%n%n%
0 0 0 0 779 56.4 166 55.3 286 59.8 270 55.1
Multivariate OR 1.00 1.00 1.00
1 1 1 1 532 38.5 118 39.3 177 37.0 196 40.0
Multivariate OR 1.06 (0.82–1.38) 0.90 (0.72–1.11) 1.06 (0.85–1.32)
1 1 0 0 2 5 1 . 831 . 081 . 781 . 6
Multivariate OR 0.55 (0.16–1.89) 0.89 (0.39–2.00) 0.90 (0.40–2.05)
1 1 1 0 1 7 1 . 282 . 730 . 661 . 2
Multivariate OR 2.42 (1.00–5.87) 0.46 (0.13–1.60) 1.03 (0.40–2.69)
Rare < 1% 29 2.1 5 1.7 4 0.8 10 2.1
Multivariate OR 0.80 (0.31–2.06) 0.41 (0.15–1.13) 0.98 (0.50–1.93)
A: rs11200014; B: rs2981579; C: rs1219648; D: rs2420946
FGFR4 Melanoma SCC BCC
Controls Cases Cases Cases
A B C n%n%n%n%
0 0 1 446 29.7 118 30.7 121 25.8 164 32.2
Multivariate OR 1.00 1.00 1.00
0 0 0 391 26.0 89 23.2 130 27.7 133 26.1
Multivariate OR 0.86 (0.63–1.17) 1.22 (0.92–1.62) 0.93 (0.71–1.21)
0 1 0 343 22.8 83 21.7 113 24.0 106 20.9
Multivariate OR 0.91 (0.66–1.26) 1.21 (0.90–1.64) 0.82 (0.62–1.10)
1 0 0 293 19.5 84 22.0 95 20.3 95 18.8
Multivariate OR 1.08 (0.78–1.49) 1.19 (0.88–1.62) 0.88 (0.66–1.18)
Rare < 1% 30 2.0 9 2.4 10 2.2 10 1.9
Multivariate OR 1.21 (0.49–2.96) 1.31 (0.55–3.10) 0.89 (0.37–2.16)
A: rs1966265*; B: rs376618; C: rs351855
0, common allele; 1, rare allele.
Logistic regression adjusted for age.
p-values for global tests are >0.05.
*The SNP rs1966265 failed the assay and the rs12519145 was genotyped instead (r2 = 0.8).BMC Cancer 2009, 9:172 http://www.biomedcentral.com/1471-2407/9/172
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study has attempted to assess the relation of the FGFR4
Gly388Arg with the progression of melanoma in
melanoma patients, and observed that the FGFR4 Arg388
allele was associated with tumor thickness and nodular
malignant melanoma [26]. We did not observe a signifi-
cant association of this allele with skin cancer risk. It
seems that this SNP acts as a potential marker for the pro-
gression of skin cancer rather than susceptibility to skin
cancer. Spinola et al. reported similar results for lung ade-
nocarcinoma, i.e., that this allele revealed association
with progression of cancer but a lack of association with
the risk of cancer [33]. FGFR2  possesses the largest
genomic structure among the FGFR family, with at least
22 exons and 21 introns and has been implicated in dis-
tinct types of cancer [47]. Also, recent in vitro and in vivo
studies showed that loss-of-function FGFR2  mutations
occur in a subset of melanomas [48]. It would be impor-
tant to comprehensively examine the association of the
common genetic variants in the entire FGFR2 gene region
with skin cancer risk.
Conclusion
In conclusion, we did not detect any contribution of
genetic variants in the FGFR2 or FGFR4 genes to inherited
predisposition to skin cancer among Caucasian women.
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